

Amy M. VandenBerg, PharmD, BCPP

Office Address:
Victor Vaughan Bldg. Room 345
1111 Catherine Street
Ann Arbor, MI 48109-2054

Contact information:
Phone: (734) 936-1622
email: amberg@med.umich.edu

Academic Positions

- 2020 to present Clinical Associate Professor
Department of Clinical Pharmacy, College of Pharmacy
University of Michigan, Ann Arbor, MI
- 2016 to 2020 Adjunct Clinical Associate Professor
Department of Clinical Pharmacy, College of Pharmacy
University of Michigan, Ann Arbor, MI
- 2002 to 2016 Adjunct Clinical Assistant Professor
Department of Clinical Pharmacy and Outcomes Sciences
Medical University of South Carolina (MUSC), College of Pharmacy
Department of Psychiatry and Behavioral Sciences
MUSC College of Medicine (2008-2016)
- 2001 to 2002 Clinical Assistant Professor
Department of Pharmacy Practice
Nova Southeastern University, College of Pharmacy
Fort Lauderdale, FL

Professional Positions

- 2016 to present Clinical Pharmacist Specialist, Psychiatry & Neurology
PGY2 Psychiatric Pharmacy Residency Program Director (RPD)
University of Michigan Health, Ann Arbor, MI
- 2002 to 2016 Clinical and Operational Pharmacy Coordinator
Clinical Pharmacy Specialist, Psychiatry
PGY2 Psychiatric Pharmacy RPD (2003 to 2016)
PGY1 with emphasis in Psychiatry RPD (2005 to 2016)
Pharmacist in Charge 2005 to 2011 and 2015 to 2016
Department of Pharmacy Services/Institute of Psychiatry (IOP)
MUSC, Charleston, SC
- 2001 to 2002 Clinical Pharmacy Specialist – South Florida State Hospital
Fort Lauderdale, FL

Education and Post-Graduate Training

- 2000 to 2001 PGY2 Psychiatric Pharmacy Practice Resident
MUSC, Charleston, SC
- 1999 to 2000 PGY1 Pharmacy Practice Resident
MUSC, Charleston, SC
- 1995 to 1999 Doctor of Pharmacy
University of Michigan - College of Pharmacy, Ann Arbor, MI
- 1991 to 1994 Bachelor of Science in Biopsychology
University of Michigan – College of LS&A, Ann Arbor, MI

Professional Licensure and Certification

2002 to present Board-Certified Psychiatric Pharmacist (recertified 2009, 2016, 2023)
 1999 to present Pharmacist, State of Michigan (License No. 5302300363)
 1999 to present Pharmacist, State of South Carolina (License No. 9958)

Recognitions, Honors and Awards

2025 Elected as Fellow of the American Association of Psychiatric Pharmacists
 2024 Nominated for Clinical Pharmacy Faculty Preceptor of the Year (Students)
 2024 Department of Pharmacy Service Recognition Level IV (scale I to IV)
 2023 Nominated for Residency Preceptor of the Year
 2022 Making a Difference Award, University of Michigan Health (clinical service/education)
 2022 Nominated for Preceptor of the Year (Students)
 2021 Making a Difference Award, University of Michigan Health (clozapine REMS update)
 2020 Making a Difference Award, University of Michigan Health (wellness initiatives)
 2020 Making a Difference Award, University of Michigan Health (wellness initiatives)
 2017 Making a Difference Award, University of Michigan Health (patient advocate)
 2016 MUSC PG3 Psychiatry Resident Didactic Teacher of the Year
 2015 MUSC PG3 Psychiatry Resident Didactic Teacher of the Year
 2013 MUSC PG3 Psychiatry Resident Didactic Teacher of the Year

Leadership in Innovative Pharmacy Practice and Education***University of Michigan Health and College of Pharmacy***

2024 Co-coordinated consolidation of psychiatric and neurologic into P612 Therapeutics to streamline teaching of topics with overlapping pharmacotherapy
 2023 Developed process for inpatient psychopharmacology stewardship
 2023 Created child-adolescent psychiatry rotation for PGY2 Pediatric Pharmacy residency
 2023 Created adult/emergency psychiatry rotation for PGY2 Emergency Medicine residency
 2023 Added child psychiatry consult as service covered by psychiatric pharmacists
 2023 Expansion of psychiatry and neurology pharmacist services (1 FTE increase)
 2020 Coordinated with interprofessional team to develop Addictions Consult service
 2019 Developed longitudinal Psychopharmacology elective for PG4 Psychiatry residents
 2018 Implemented weekly patient medication education groups for psychiatry partial program
 2017 Expanded psychiatric clinical pharmacy coverage to psychiatry emergency
 2017 Introduced weekly patient medication education groups for inpatient adult psychiatry
 2016 PGY2 Psychiatric Pharmacy Residency – ASHP Approved for Pre-Candidate status

Medical University of South Carolina

2015 Developed and operationalized Collaborative Drug Therapy Management (CDTM) protocol for naltrexone LAI
 2014 Developed and operationalized CDTM for adult depression
 2010 Implemented pharmacist medication reviews in Behavioral Medicine clinic
 2008 Developed and operationalized CDTM protocol and clinic for LAI antipsychotics
 2008 Implemented automatic therapeutic substitution for desvenlafaxine-venlafaxine, bupropion IR-SR-XL
 2007 Implemented automatic therapeutic substitution for paliperidone-risperidone, hydroxyzine HCL-hydroxyzine pamoate,
 2005 Developed online psychiatry nursing and medical assistant staff training modules for psychopharmacology
 2004 Established requirement for Psychiatric Pharmacist approval of all inpatient orders for clozapine and LAI antipsychotics (early example of psychopharmacology stewardship)
 2002 Implemented new employee orientation psychopharmacology review for all Institute of Psychiatry staff (RN, therapeutic assistant, MSW)

Scholarly Activity***Peer-Reviewed Journal Articles:***

Note: *Pharmacy student/resident under my direction, #Medical student/resident under my direction

44. *O'Connell M, **Vandenberg A**. Clinical Pearls for the management of duloxetine in patients with medical comorbidities. *Ment Health Clin*. 2024;14(6):313-320. DOI: 10.9740/mhc.2024.12.313
43. *Ernst K, Thompson AN, **Vandenberg A**. Relative exposure to psychiatric conditions and medications in pharmacy education. *Currents in Pharmacy Teaching and Learning*. Online December 29, 2023. DOI: 10.1016/j.cptl.2023.12.016
42. Im DS, *Capitanov M, **Vandenberg AM**. Loxapine in the treatment of manic and psychotic symptoms in an individual intolerant to multiple mood-stabilizing and antipsychotic medications. *Case Reports in Psychiatry*. 2023. doi: 10.1155/2023/8887553
41. *Marriott M, *Schwery A, **Vandenberg A**. Myasthenia gravis: what does a pharmacist need to know? *Am J Health Syst Pharm*. 2023;80(5):247-257 doi: 10.1093/ajhp/zxac343
40. Winder GS, Andrews SR, Banerjee AG, Hussain F, Ivkovic A, Kuntz K, Omary L, Rasimas JJ, Shenoy A, Thant T, **Vandenberg A**, Zimbrea P. Cannabinoid and solid organ transplantation: psychiatric perspectives and recommendations. *Transplantation Reviews*. 2022;36(4). <https://doi.org/10.1016/j.trre.2022.100715>
39. **Vandenberg, AM**. An update on recently approved long-acting injectable antipsychotics: Knowns and unknowns regarding their use. *Ment Health Clin* 2022;12(5):270-281. doi: 10.9740/mhc.2022.20.270.
38. *Wartman CC, **Vandenberg A**. Valproate: Not all boxed warnings are created equal. *Ann Pharmacother*. 2022;56(12):1349-1355.
37. *O'Connell, M, **Vandenberg A**. Impact of pharmacist driven medication reconciliation in psychiatric emergency services on length of stay, medication errors, and medication discrepancies. *Drug & Therapy Perspectives*. 2021;37:175-180.
36. *Erley J, *Goldsborough S, **Vandenberg A**, Audu A. Loxapine in a patient with clozapine-resistant psychosis. *Ment Health Clin*. 2021;11(4):263-266.
35. #Ju V, *Walkerly A, **Vandenberg A**, Shobassy A. Atomoxetine-induced seizures and psychosis due to concomitant use of bupropion: a case report. *J Clin Psychopharmacol*. 2022;42(6):600-602. doi: 10.1097/JCP.0000000000001614
34. #Brelje A, #Fay B, Marriow S, **Vandenberg A**. Transaminitis with psychosis: Identifying drug induced liver injury in the setting of acute hepatitis C. *Ment Health Clin*. 2022;12(3):210-213. doi: 10.9740/mhc.2022.06.210.
33. *Walkerly A, Leader LD, Cooke E, **Vandenberg A**. Review of allopregnanolone agonist therapy for the treatment of depressive disorders. *Drug Des Devel Ther*. 2021;15:3017-3026.
32. *Irwin M, **Vandenberg A**. Retracing our steps to understand ketamine in depression: a focused review of hypothesized mechanisms of action. *Ment Health Clin*. 2021;11(3):200-210.
31. *O'Connell M, **Vandenberg A**. Impact of pharmacist driven medication reconciliation in psychiatric emergency services on length of stay, medication errors and medication discrepancies. *Drugs Ther Perspect*. 2021;37:175-180.
30. *O'Connell M, **Vandenberg A**. Vertigoheel induced psychosis: a patient case report. *Ment Health Clin*. 2021;11(1):31-34.
29. *Cusimano J, **Vandenberg A**. Low-hanging fruit for getting back on your feet: a critical review of diet and exercise interventions for depression. *J Aff Disord Reports*. 2020;12(1). online
28. *Chow CL, *Kadouh NK, Bostwick JR, **Vandenberg AM**. Akathisia and newer second-generation antipsychotic drugs: a review of current evidence. *Pharmacotherapy*. 2020;40(6):565-574.
27. *O'Connell M, **Vandenberg A**. CYP450 interactions between illicit substances and prescription medications. *Current Psychiatry*. 2020; 19(8):40-42. doi: 10.12788/cp.0288
26. *Cusimano J, Martin C, **Vandenberg A**. Olanzapine-associated edema and decreasing serum lithium concentrations: a case report. *J Clin Psychopharm*. 2020;40(5):499-500.
25. *Cusimano J, **Vandenberg A**. Long-acting injectable antipsychotics and their use in court-ordered treatment: A cross-sectional survey of psychiatric pharmacists' perceptions. *Ment Health Clin*. 2020;10(1): 18-24.

24. Leader LD, *O'Connell M, **VandenBerg A**. Brexanolone for postpartum depression: clinical evidence and practical considerations. *Pharmacotherapy*. 2019;39(11):1105-12.
23. *Bixby AL, *Goldsborough S, #Iuppa A, #LeBlanc A, Schultz HE, **VandenBerg A**. Successful use of carbamazepine in a patient with drug rash with eosinophilia and systemic symptoms. *Ment Health Clin*. 2019;9(5): 331-5.
22. *Bixby AL, **VandenBerg A**, Bostwick, J. Clinical Management of Bleeding Risk with Antidepressants. *Ann Pharmacother*. 2018; (e pub; doi 10.1177/1060028018794005)
21. McGrane I, **VandenBerg A**, Munjal R. Treatment of pseudobulbar affect with fluoxetine and dextromethorphan in a woman with multiple sclerosis. *Ann Pharmacother*. 2017; 51(11): 1035-6.
20. *Bacon O, **VandenBerg A**, *May M. Provider and patient perception of psychiatry patient health literacy. *Pharm Pract*. 2017; 15(2):908-12.
19. *Colvard M, Jackson M, *Oliveira R, *Scholtes K, Burghart S, Gutierrez C, **VandenBerg A**. Consumer satisfaction with national alliance on mental illness written medicine information. *Ment Health Clin*. 2017;7(2):74-80
18. **VandenBerg A**, Broadway J. Enteral administration of protein supplement and valproate: a potential pharmacokinetic interaction. *Ment Health Clin*. 2017; 7(1):10-12.
17. **VandenBerg A**, Broadway J, Lalich C, Kennedy R, Williams K. Valproate serum concentrations in patients with hypoalbuminemia and medical complications. *Ment Health Clin*. 2017; 7(1):13-15.
16. *Bacon O, Robert S, **VandenBerg A**. Evaluating nursing satisfaction and utilization of the Clinical Institute Withdrawal Assessment for Alcohol, revised version (CIWA-Ar). *Ment Health Clin*. 2016;6(3):114-9.
15. *May M, **VandenBerg A**. The role of methylphenidate in depression. *Ment Health Clin*. 2015; 5(6): 271-6.
14. *Sigler M, **VandenBerg A**, Thompson A. Evidence and clinical considerations for the use of serotonin and norepinephrine reuptake inhibitors in the treatment of painful neuropathy. *Ment Health Clin*. 2015; 5(6): 289-95.
13. Gwynette MF, Beck B, **VandenBerg A**, Stocking N. Under arrest: the use of amantadine for treatment-refractory mood lability and aggression in a patient with traumatic brain injury. *J Clin Psychopharmacol*. 2015;35(1):102-4.
12. *Freeland KN, *Cogdill, BR, *Ross Ca, *Sullivan CO, Drayton SJ, **VandenBerg AM**. Adherence to evidence-based treatment guidelines for bipolar depression in an inpatient setting. *AJHP*. 2015.72(23):S156-S161.
11. **VandenBerg A**, Mullis D. Integrating psychiatric PharmD services into an emergency department psychiatry team. *Ment Health Clin*. 2014;14(6):279-82.
10. **VandenBerg A**. What's new? Isomers, metabolites and prodrugs, oh my! *Ment Health Clin*. 2014;4(1):1.
9. **VandenBerg A**. What is the difference? Within class comparisons of psychotropic agents with new products. *Ment Health Clin*. 2014;4(1):2-7.
8. *Ross C, **VandenBerg A**, Borckardt J, Short EB. Impact of pretreatment with amobarbital on electroconvulsive therapy outcomes. *J ECT*. 2013;29(1):e10-11.
7. Hebbard AM, *Colvard MJ, Book SW, **VandenBerg AM**. Development of a collaborative drug therapy management protocol for extended-release intramuscular naltrexone. *Ment Health Clin*. 2013; 3(6):292-294.
6. *Miller DF, *Garcia D, *Kreys TJ, *Phan SV, **VandenBerg A**, Garrison KL. Evaluating the Quality of Performance of Medication Reconciliation on Hospital Admission. *Hosp Pharm*. 2012;47(7):526-531
5. *Phan SV, **VandenBerg AM**. Financial impact of a pharmacist-managed clinic for long-acting injectable antipsychotics. *AJHP*. 2012;69:1014-1015.
4. *Freeland KN, **VandenBerg A**. Pharmacologic Options for the Management and Prevention of Migraines. *J Pharm Technol*. 2011;27:222-8.
3. #Snarr BS, *Phan SV, #Garner A, **VandenBerg AM**, Barth KS. Symptomatic Bradycardia with Oral Aripiprazole and Oral Ziprasidone. *Ann Pharmacother*. 2010;44:760-3.
2. *Lorenz R, **VandenBerg AM**, #Canepa E. Serotonergic antidepressants and linezolid: a retrospective chart review and presentation of cases. *Int J Psych Med*. 2008;38(1):81-90.
1. Wright T, **VandenBerg AM**. Risperidone- and quetiapine-induced cholestasis. *Ann Pharmacother*. Sept 2007;41(9):1518-23.

Book Chapters:

7. **VandenBerg AM.** Depressive Disorders. In: DiPiro J, et al eds. In: *DiPiro's Pharmacotherapy: A Pathophysiologic Approach. 13th Edition.* McGraw-Hill; *publication pending.*
6. **VandenBerg AM.** Depressive Disorders. In: DiPiro J, et al eds. In: *DiPiro's Pharmacotherapy: A Pathophysiologic Approach. 12th Edition.* McGraw-Hill; 2023.
5. Jones J, **VandenBerg A,** Malcolm R. Benzodiazepines and Other Sedative Hypnotics. In: *Textbook of Substance Abuse Treatment.* 6th ed. Arlington, VA. American Psychiatric Publishing; 2019.
4. **VandenBerg AM.** Major Depressive Disorder. In: DiPiro J, et al eds. In: *DiPiro's Pharmacotherapy: A Pathophysiologic Approach. 11th Edition.* McGraw-Hill; 2019.
3. Werremeyer A, **VandenBerg A.** Headache. In: Murphy J, Lee M, eds. *Pharmacotherapy Self-Assessment Program, 2013-2015 series.* CNS/Pharmacy Practice Module. Kansas City, MO: American College of Clinical Pharmacy, 2015.
2. Swidan S, **VandenBerg AM.** Headache. In: Mueller B, Bertch K, Dunsworth T, et al, eds. *Pharmacotherapy Self-Assessment Program, 4th ed.* Psychiatry/Neurology Module. Kansas City, MO: American College of Clinical Pharmacy, 2002.
1. **VandenBerg A.** Monographs for mayapple, marigold, meadowsweet, marshmallow, marjoram. *Nursing Herbal Drug Handbook.* Springhouse, PA: Springhouse Corp., 2001.

Letters to the Editor, Editorials and Book Reviews:

6. **VandenBerg AM,** Davis EAK. 2023 MHC Awards and Recognition. *Ment Health Clin.* 2024;14(2):79-81.
5. **VandenBerg AM.** Response to comment on the recently published article "An update on recently approved long-acting injectable second-generation antipsychotics: knowns and unknowns regarding their use". *Ment Health Clin.* 13(3):167-168.
4. Davis EAK, **VandenBerg AM.** 2022 MHC Awards and Recognition. *Ment Health Clin.* 2023;13(1):1-3.
3. **VandenBerg AM,** Davis EAK. 2021 MHC Awards and Recognition. *Ment Health Clin.* 2022;12(2):54-56.
2. **VandenBerg AM,** Davis EAK. 2020 MHC Awards and Recognition. *Ment Health Clin.* 2021;11(3):173-174.
1. **VandenBerg AM.** Book Review Handbook of Drug Interactions: A Clinical and Forensic Guide, 2nd ed. *Ann Pharmacother.* 2012; 46(6):906-907.

Abstracts/Posters

Note: *Pharmacy student/resident under my direction, #Medical student/resident under my direction

45. *Penton J, **VandenBerg A.** Evaluating the use and monitoring of naltrexone in hospitalized patients. ASHP Midyear Meeting Vizient Poster, December 7, 2024.
44. *He I, **VandenBerg A.** Use and monitoring of lithium in hospitalized patients. ASHP Midyear Meeting Vizient Poster, December 7, 2024.
43. *Wang C., **VandenBerg A.** Assessment of renal dose adjustments for psychotropic medications in hospitalized patients. ASHP Midyear Meeting Vizient Poster, December 7, 2024.
42. *Dean M, *Capitanov M, **VandenBerg A.** Lithium dosing in post-transplant patient with unstable fluid-electrolyte status. AAPP Annual Meeting April 18, 2023
41. *Capitanov M, **VandenBerg A.** Clinical conundrums of clozapine on consult liaison psychiatry. AAPP Annual Meeting April 18, 2023
40. #Brelje A, #Fay B, Mariouw S, **VandenBerg A.** Identifying olanzapine induced liver injury in the setting of acute hepatitis C. Michigan Psychiatric Society Spring Meeting; April 14, 2022
39. *Christensen H, **VandenBerg A.** Home antidepressant prescribing during non-psychiatric hospitalization. CPNP Annual meeting, April 24, 2022.

38. *Ernst K, **Vandenberg A**, Thompson A. Relative exposure to psychiatric disease states and medications in pharmacy education. APhA Oct 27, 2021
37. *Walkerly A, **Vandenberg A**. Free and total serum valproic acid concentrations: association with clinical response and toxicities. CPNP 2021 Virtual Annual Meeting (associated platform presentation and **resident research award**)
36. *Cusimano J, **Vandenberg A**. Impact of medications on electroconvulsive therapy outcomes. CPNP 2020 Virtual Annual Meeting.
35. *Cusimano J, Martin C, **Vandenberg A**. Olanzapine-induced Edema Decreasing Lithium Concentrations. CPNP 2019 Annual Meeting. Salt Lake City, UT
34. *O'Connell M, #Hunt E, **Vandenberg A**, Vertigoheel Induced Psychosis: A Case Report. CPNP 2019 Annual Meeting. Salt Lake City, UT
33. *O'Connell M, **Vandenberg A**. Impact of pharmacist driven medication reconciliation in psychiatric emergency services on patient outcomes. CPNP 2019 Annual Meeting. Salt Lake City, UT
32. *Goldsborough S, *Bixby A, #Iuppa A, #LeBlanc A, Schultz H, **Vandenberg A**. Successful use of carbamazepine in a patient with drug rash with eosinophilia and systemic symptoms. CPNP 2018 Annual Meeting, Phoenix, AZ.
31. *Goldsborough S, *Erley J, **Vandenberg A**, Audu A. Loxapine in patient with clozapine-resistant psychosis. CPNP 2018 Annual Meeting, Phoenix, AZ.
28. Brueckner E, Robert S, *Linder L, *Ruhe AM, **Vandenberg A**. Creative pharmacokinetics utilized for improved efficacy in the treatment of pseudobulbar affect: combining SSRIs with dextromethorphan. South Carolina Psychiatric Association Annual Meeting Charleston, SC January 27, 2017.
27. **Vandenberg A**, Hallman I, Hilderbrand K, Kinsman J, Hirshbein L. Management of anxiety and agitation using electronic medical record to optimize care and interdisciplinary communication. CPNP Annual Meeting Phoenix, AZ April 2017
26. **Vandenberg A**. Loxapine in patient with possible clozapine-induced myocarditis. CPNP Annual Meeting Phoenix, AZ April 2017
25. McGrane I, **Vandenberg A**, Munjal R. Treatment of pseudobulbar affect with fluoxetine and dextromethorphan in a woman with multiple sclerosis: a case report. CPNP Annual Meeting Phoenix, AZ April 2017
24. *Bacon O, **Vandenberg A**, May M. Provider and patient perception of patient health literacy. CPNP Annual Meeting Colorado Springs, CO April 2016
23. *Bacon O, Robert S, **Vandenberg A**. Evaluating nursing satisfaction and utilization of the clinical institute withdrawal assessment for alcohol, revised version (CIWA-Ar). CPNP Annual Meeting Tampa, FL April 2015.
22. *May M, **Vandenberg A**. Assessment of factors leading to 30-day psychiatric readmissions. CPNP Annual Meeting Tampa, FL April 2015.
21. *Crawford RE, **Vandenberg A**, Borckhardt J. Continuation of Asenapine, Iloperidone, and Lurasidone Versus Haloperidol and Risperidone During Inpatient Psychiatric Hospitalizations: a Retrospective Chart Review. CPNP Annual Meeting Phoenix, AZ April 2014
20. *Colvard MJ, *Jackson M, *Oliveira R, *Scholtes K, Burghart S, Gutierrez C, **Vandenberg A**. Evaluation of Consumer and Provider Satisfaction with National Alliance on Mental Illness Written Medicine Information: A multi-site, collaborative pharmacy resident project. CPNP Annual Meeting Colorado Springs, CO April 2013
19. *Jackson MT, *Colvard MJ, *Oliveira R, *Scholtes K, Burghart S, Gutierrez C, **Vandenberg A**. Collaborating Across the Country: Lessons Learned from a Multi-site, Pharmacy Resident Research Project. CPNP Annual Meeting Colorado Springs, CO April 2013
18. *Ross CA, *Cogdill B, **Vandenberg A**. Implementation and Assessment of a Psychiatric Pharmacist in the Behavioral Medicine Clinic. CPNP Annual Meeting Tampa, FL April 2012
17. *Ross CA, **Vandenberg A**. Neuroleptic Malignant Syndrome with Concomitant Lamotrigine-Induced Rash: A Case Report. CPNP Annual Meeting Tampa, FL April 2012.
16. *Freeland KN, **Vandenberg A**. Incidence and Course of Neuroleptic Malignant Syndrome in Patients Treated with Atypical Antipsychotics. CPNP Annual Meeting Phoenix, AZ April, 2011.
15. *Ross CA, **Vandenberg A**. Impact of Pre-Treatment with Amobarbital on ECT Outcomes. CPNP Annual Meeting, Phoenix, AZ April, 2011.

14. *Freeland KN, *Ross CA, *Cogdill B, Drayton SJ, Short BA, **Vandenberg AM**. Adherence to Evidence Based Treatment for Bipolar Depression – A Retrospective Review. ASHP Midyear Meeting Anaheim, CA December 2010.
13. *Phan SV, **Vandenberg A**. Cost Impact of a Pharmacist-Managed Long-Acting Injectable Antipsychotic Clinic. CPNP Annual Meeting, San Antonio, TX, April 19, 2010.
12. *Kreys TJ, **Vandenberg A**, Drayton S. Outpatient Compliance Rates with Long-Acting Injectable Antipsychotic Therapy. CPNP Annual Meeting, San Antonio, TX, April 19, 2010.
11. *Miller D, *Garcia D, *Kreys TJ, *Phan S, **Vandenberg A**, Garrison K. Evaluation of Accuracy of Medication Reconciliation Obtained Upon Hospital Admission at an Academic Medical Center. ASPH Midyear Clinical Meeting, Las Vegas NV, December 5, 2010.
10. *Lemacks L, **Vandenberg A**. Automatic Therapeutic Substitution (ATS) of Risperidone and Paliperidone in Both Adult and Pediatric Patients. CPNP Annual Meeting, Scottsdale, AZ, April 13, 2008
9. *Lorenz R, **Vandenberg A**. Medication Reconciliation in a Psychiatric Hospital. CPNP Annual Meeting, Scottsdale, AZ, April 14, 2008.
8. *Lorenz R, *Thompson A, *Maughan M, *Guirguis A, **Vandenberg A**. Atypical Antipsychotic Polypharmacy: Documentation of Rationale. ASHP Midyear UHC Poster Presentation, Anaheim, CA, December 2006
7. *Lorenz R, **Vandenberg AM**. Assessment of Vital Signs in Children and Adolescents Taking ADHD Medication. CPNP Annual Meeting, Baltimore, MD, April 2006
6. *Slunaker DL, **Vandenberg AM**, Drayton SJ. Evaluation of the Timeline to Maintenance Antipsychotic Therapy in an Inpatient Psychiatric Hospital. CPNP Annual Meeting, Baltimore, MD, April 2006
5. *Mikeworth, MM, **Vandenberg, AM**, Hazy, J. Development and Implementation of Computerized Staff Training Modules to Teach Psychopharmacology (poster) College of Psychiatric and Neurologic Pharmacists Annual Meeting, San Diego, CA, March 2005.
4. *Garris, S., **Vandenberg, AM**, MacFall, H. Evaluation of Ziprasidone Mesylate Guidelines for Use at the Medical University of South Carolina (MUSC) (poster) College of Psychiatric and Neurologic Pharmacists Annual Meeting, San Diego, CA, March 2005
3. *Bullington, W., **Vandenberg, AM**, Wagner, M., McHugh, K. Development of Dose-based Guidelines of Psychotropics in Children (poster) American College of Clinical Pharmacy, Myrtle Beach, SC, April 2005
2. **Vandenberg AM**, Jackson CW. "Assessment of Falls in Non-Geriatric Psychiatry Inpatients." ACCP Spring Research Forum, 2002, April 16, Savannah, GA.
1. Swidan S, Townsend KA, **Vandenberg AM**, Yarows SA. Management of Hypertension in Hospitalized Elderly Patients. American Society of Hypertension Scientific Meeting 2000, May 20, New York, NY.

Editorial Activities

- | | |
|--------------|--|
| 2020-present | DiPiro J, ed. by. Pharmacotherapy: A Pathophysiologic Approach. Editions e11, e12, 12, and 13. Assistant Editor for Psychiatry, Neurology, Gynecologic and Obstetric Disorders |
| 2015-present | CPNP/AAPP Mental Health Clinician Senior Editor <ul style="list-style-type: none"> - Successfully collaborated to transition journal from editor-solicited to open submission while growing peer-reviewer pool - Collaborated with Coordinating Editor for journal indexing in PubMed, Google Scholar, and Scopus - Coordinated to publish AAPP annual meeting poster abstracts in journal - Coordinated with AAPP BCPP Recertification Committee to publish annual issue offering 4 hours of BCPP recertification CE credit - Review and make final publication decision on 40-50 manuscripts annually |
| 2013-2015 | CPNP Mental Health Clinician Handling Editor <ul style="list-style-type: none"> - Coordinated 6-7 authors and theme for one issue annually |
| 2007-2013 | CPNP/NAMI – Medication Fact Sheet Co-Editor <ul style="list-style-type: none"> - Developed and applied templates for over 40 individual medication fact sheets |

Peer-reviewed Collaborative Practice Guidelines***Medical University of South Carolina***

Pharmacist Antidepressant Management

- Continuation, taper and titration of oral antidepressants

Pharmacist LAI Naltrexone Management

- Naltrexone administration
- Urine drug screen and liver function test monitoring
- Education and consent documents

Pharmacist LAI Antipsychotic Management

- Haloperidol, fluphenazine, risperidone, paliperidone, aripiprazole administration
- Abnormal involuntary movement scale and EPS monitoring
- Oral antipsychotic taper
- Anticholinergics and propranolol for adverse effects
- Metabolic monitoring

Service Grants

Community Foundation for Southeast Michigan Medicine

10/1/2021 to 9/30/2022

Title: 492437-Sub of N031744-The Michigan Medicine ED to Community Care Transition Model

Amount: 5% effort

Presentations***Platform/Webinar/Podcast/Invited Presentations:***

28. Case Presentation & Panel Discussion: Acute Psychosis, diagnosis, treatment and recovery in a U-M student. (Interprofessional Case Conference, CME). September 17, 2024
27. Breaking Down Mental Health Podcast (ACCME): Antidepressants in Child-Adolescent Psychiatry (Podcast). February 22, 2024
26. General Session Residency panel: Inclusion of SDoH Education in Pharmacy Training Programs. Michigan Society of Health-System Pharmacists Annual Meeting; Lansing, MI (ACPE). October 27, 2023
25. What's Our Worth? Demonstrating the Impact and Value of Clinical Services. American Psychiatric Association Mental Health Services Conference; Washington DC (CME). October 13, 2023
24. Rapid Responses: Management of Psychiatric Emergencies. American Association of Psychiatric Pharmacists Annual Meeting; Atlanta, GA. (ACPE). April 18, 2023
23. Medications for ADHD: The New and the Reinvented; Michigan Institute for Care Management & Transformation (Nursing and Social Work CE). April 14, 2022
22. Wellness, Resilience and Burnout in Pharmacy Residency Training; Michigan Society of Health-System Pharmacists (ACPE). October 13, 2020
21. Psychopharmacology Update; Michigan Medicine Psychiatric Emergency Services (CNE). August 26, 2019
20. Southeastern Michigan Society of Health-System Pharmacists. Psychotropics: The New, the Old and the Reinvented (ACPE). February 13, 2019
19. Medication Management and ECT; Michigan Medicine ECT Nursing Staff (CNE). December 11, 2018
18. Pain Management in Psychiatry; Michigan Medicine Psychiatric Emergency Service RN Education Series (CNE). October 3, 2018
17. Treatment of BPSD; Dementia, What Now? Interventions for the Patient and Caregiver After the Diagnosis Conference (CME and SW CE). September 27, 2018
16. Treatment of Acute Agitation and Anxiety in Inpatient Psychiatry; Psychiatry Nursing Education Day (CNE). December 7, 2017
15. Tom D. Rowe 66th Annual Pharmacy Lectures: Psychiatric Pharmacy Now and Future (ACPE). October 26, 2017
14. Treatment of Major Depressive Disorder: Old Dogs, New Tricks; SCSHP Annual Meeting (ACPE). March 13, 2016
13. Impact of Drug Shortages on the Provision of ECT; CPNP Annual Meeting (ACPE). April 28, 2014

12. Treatment of Major Depressive Disorder: Old Dogs, New Tricks; Family Medicine New Drug Update (CME). May 17, 2013
11. “New” Medications on the Horizon; Spoleto Update (CME). May 29, 2009
10. ADHD Update; Spoleto Update (CME). April 2008
9. ADHD Update; SCSHP Annual Meeting (ACPE) November 4, 2007
8. Dealing with Psychiatric Issues in Medically Ill Patients; SCSHP Spring Symposium (ACPE). March 6, 2007
7. Prevention of Patient Falls; Med U Way Series (ACPE, CME, CNE). January 20, 2005
6. Update on Bipolar Disorders and Treatment; Family Medicine Annual New Drug Update (CME). May 20, 2004
5. Appropriate Use of Atypical Antipsychotics in the Hospital Setting; Med U Way Series (ACPE, CME, CNE). January 15, 2004
4. Management of Treatment Resistant Schizophrenia; 23rd National Symposium for Psychiatric Practitioners (ACPE, CNE). February 4, 2003
3. Antidepressants in Coronary Artery Disease – A Changing Role; SCSHP Fall Symposium (ACPE). October 10, 2002
2. Use of Atypical Antipsychotics in the Treatment of Bipolar Disorder. MUSC Pharmacy Residency Seminar series (ACPE). November 27, 2000
1. Analgesic Abuse Headaches. MUSC Pharmacy Residency Seminar series (ACPE). March 27, 2000

Research Activities

Industry-Funded

4. A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects with Schizophrenia. Protocol # R092670PSY3011: Study Drug Manager (2012-2015)
3. A Fifteen Month, Prospective, Randomized, Active-Controlled, Open-Label, Flexible-Dose Study of Paliperidone Palmitate Compared with Oral Antipsychotic Treatment in Delaying Time to Treatment Failure in Adults with Schizophrenia Who Have Been Incarcerated” Protocol #: R092670SCH3006; Phase 4: Study Drug Manager (2010-2015)
2. Covance Clinical Study #30-07-247 DeVane (PI) A 38-week, Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients with Schizophrenia: Study Drug Manager (2009-2015)
1. Covance Clinical Study # 31-108-248 DeVane (PI) A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients with Schizophrenia: Study Drug Manager (2009-2015)

Quality Assurance/Quality Improvement

45. Evaluation of Impact of Oral Antipsychotic Overlap for Paliperidone LAI (2024)
44. Development of Inpatient Psychotropic Stewardship Program in an Academic Medical Center (2023)
43. Clinical conundrums of clozapine on consult liaison psychiatry (2022)
42. Relative exposure to psychiatric disease states and medications in pharmacy education. (2021)
41. Home antidepressant prescribing during non-psychiatric hospitalization (2021)
40. Potential interactions between marijuana and psychotropic medications prescribed on inpatient psychiatry unit (2020)
39. Impact of order set changes on utilization of oral lorazepam (2020)
38. Clinical implications of free vs total valproic acid levels (2020)
37. Optimizing use of antidepressant medications in primary care (2019)
36. Patterns of medication use surrounding episodes of violent physical restraints (2019)
35. Effect of medications on electroconvulsive therapy outcomes (2019)
34. Impact of Psychiatric Pharmacist Medication Reconciliation in Psychiatric Emergency Services (2018)
33. VTE Risk Assessment on general adult inpatient psychiatry (2017)
32. Needs assessment for psychiatric pharmacy services (2017)
31. Assessment of Documentation of PRN medication administration (2015)

30. Impact of 30-day Supply of Discharge Medications on 30-day Rehospitalization Rates (2015)
29. Patient vs Staff Impression of Health Care Literacy in Psychiatric Patients (2015)
28. Staff Satisfaction and Competency for CIWA-Ar (2014-2015)
27. Assessment of 30-day Rehospitalization in a Psychiatric Hospital – Contributing Factors (2014)
26. Continuation of Asenapine, Iloperidone, and Lurasidone Versus Haloperidol and Risperidone During Inpatient Psychiatric Hospitalizations: a Retrospective Chart Review (2013)
25. Assessment of Quality and Accuracy of Discharge Medication Reconciliation in Patients with Psychiatric Illness (2012)
24. Collaborating Across the Country: Lessons Learned from a Multi-site, pharmacy resident research project (2012)
23. Evaluation of Consumer and Provider Satisfaction with NAMI Written Medicine Information (2012)
22. Implementation of PharmD Services in a Behavioral Medicine Clinic (2011)
21. Retrospective Review of the Incidence and Course of Neuroleptic Malignant Syndrome Associated with Atypical Antipsychotics (2010)
20. Impact of Pre-treatment with Amobarbital on ECT Outcomes (2010)
19. Retrospective Review of Clinical Outcomes in Geriatric Patients Receiving Nortriptyline Post-ECT (2010)
18. Financial Impact of PharmD Run Long-Acting Injectable Antipsychotic Clinic (2009)
17. Rate of 6-Month Follow Up for Long-Acting Injectable Antipsychotics Initiated During Hospitalization (2009)
16. Evaluation of Quality of Inpatient Medication Reconciliation (2009)
15. Survey of Physician Perspectives on Automatic Therapeutic Substitutions of Psychiatric Medications (2008)
14. Outpatient Outcomes Following Automatic Therapeutic Substitution of Risperidone to Paliperidone Upon Discharge from Inpatient Psychiatry (2008)
13. Evaluation of Low Dose Quetiapine Use in a Psychiatric Hospital (2007)
12. Assessment of Automatic Therapeutic Substitution Protocol for Paliperidone in a Psychiatric Hospital (2007)
11. Retrospective Review of Concurrent Linezolid and SSRI Therapy (2006)
10. Appropriateness of Therapeutic Drug Monitoring for Mood Stabilizers (2006)
9. Evaluation of Medication Reconciliation Process in a Psychiatric Hospital (2006)
8. Review of Long-Acting Injectable Risperidone in a Psychiatric Hospital (2006)
7. Atypical Antipsychotic Polypharmacy: Documentation of Rationale in Patient Charts (2005)
6. Evaluation of Timeline to Maintenance Antipsychotic Therapy (2005)
5. Assessment of Vital Signs in Children and Adolescents Receiving Medication for the Treatment of ADHD (2005)
4. Monitoring Metabolic Side Effects of Atypical Antipsychotics (2004)
3. Adherence to Prescribing Criteria for Intramuscular Ziprasidone (2003)
2. Prevalence of Atypical Antipsychotic Polypharmacy and Related Outcomes (2003)
1. Assessment of Falls in Non-Geriatric Psychiatry Inpatients (1999)

Other Research-Related Activities

- | | |
|--------------|---|
| 2010 to 2016 | Data Safety Monitoring Board (DSMB): Naltrexone in alcoholics with and without the asp40 OPRM1 gene (PI: Raymond Anton) |
| 2009 to 2016 | DSMB: NAC for cannabis dependence in adolescents (PI: Kevin Gray) |
| 2007 to 2016 | DSMB: Modafinil for cocaine dependence (PI: Raymond Anton) |
| 2007 to 2016 | DSMB: NAC for cocaine dependence (PI: Raymond Anton) |

Teaching and Mentoring**Didactic Courses**

Academic Year	Course	Topics	Hours/ Term	Students Enrolled	Score
University of Michigan College of Pharmacy					
2025	Therapeutic Problem Solving (P612)	Epilepsy, Status Epilepticus, Dementia	15.5	83	TBD
2024		Parkinson disease, Headache	15.5	75	4.88
2023			14.5	82	4.86
2022			14.5	81	4.73
2021			14.5	78	3.73
University of Michigan School of Nursing					
2025	Pharmacotherapeutics II (P621)	Antiseizure medications,	12	83	TBD
2024		antidepressants,	12	99	4.9
2023		anxiolytics and	12	95	4.78
2022		sedative hypnotics	12	124	4.14
2021			8	135	4.15
Medical University of South Carolina College of Pharmacy					
2003 to 2008	Geriatrics Elective	Psychotropics in the Elderly	2	~75	NA
2003 to 2008	Disease State Management II	Headache	2	~75	NA
Nova Southeastern University					
2002	Disease State Management	Psychotropics	4	~80 + remote campuses	NA

Guest Lecturing University of Michigan

Term	Department, Course Name or No	Contact Hrs/term	# Students/session
FA 2024 WN 2021 FA 2017 to 2020	Social Work Behavioral, Psychological and Ecological Aspects of Health, Mental Health and Disease	1	~30
FA 2023	Pharmacy P704, Social Justice Grand Rounds: Eating Disorders	1	~80
2019 to 2023	Medicine, M4 Psychiatry and Neurology Residency Prep Course	3	~20
2016 to 2020	Medicine, M2 Psychiatry Sequence Case discussion leader	3	~80

Student Medication Use Evaluations

November 2024	Pregnancy testing and education documentation for valproate products in hospitalized patients who can become pregnant
November 2022	Appropriate dosing and administration of long-acting injectable antipsychotics
November 2022	Documentation and management of inpatient missed oral contraceptive doses
November 2022	Rate of appropriate metabolic monitoring for antipsychotics

Experiential Rotations (IPPE and APPE)

Years	Rotation Type	# of Student Rotation Months
University of Michigan Health		Total: 53
2016 to present	APPE Psychiatry and Neurology	47 (average 6 per year)
2016 to present	IPPE Inpatient Clinical	6
Medical University of South Carolina		Total: 94
2003 to 2016	APPE Psychiatry	94

Physician Resident/Fellow Didactic Teaching

Years	Audience	Title	Average Hrs/yr	Average # Residents/Class
University of Michigan Department of Psychiatry				
2018 to present	Psychiatry Fellows	CORE Lecture Series	4	5
2018 to present	PG4 Psychiatry Residents	Psychopharmacology CORE Lecture Series	8	15
2018 to present	PG2 Psychiatry Residents	Monthly Lunch & Learn – Psychopharmacology Pearls and Updates	12	15
Medical University of South Carolina Department of Psychiatry				
2008 to 2016	Psychiatry Fellows	Geriatric and Child-Adolescent Psychopharmacology	6	8
2006 to 2016	PG1-5 Psychiatry Residents	Monthly psychopharmacology update	12	35
2004 to 2016	PG3 Psychiatry Residents	Psychopharmacology Weekly Seminar	48	15

Postgraduate Pharmacy Residency Training:***Residency Program Director (PGY2 Psychiatric Pharmacy and PGY1 with emphasis in Psychiatry)***

Resident	Year Graduated	Current Position
Chloe Matecki, PharmD	Pending 2025	TBD
Meagan Dean, PharmD	2024	Clinical Pharmacy Specialist, PGx and Mental Health; VA Hospital, Saginaw, MI
Marina Capitanov, PharmD, BCPP	2023	Clinical Specialist, Psychiatry Trident Health, Charleston, SC
Hannah Christensen, PharmD, BCPP	2022	Clinical Specialist, Psychiatry Seattle Children's Hospital, Seattle, WA
Autum Walkerly, PharmD, BCPP	2021	Clinical Specialist, Psychiatry Department of Mental Health, Los Angeles, CA
Joe Cusimano, PharmD, BCPP	2020	Pharmacovigilance Safety Program FDA, Bethesda, MD
Megan O'Connell, PharmD, BCPP	2019	Clinical Specialist, Psychiatry & Neurology University of Michigan Health, Ann Arbor, MI
Sarah Goldsborough, PharmD, BCPP	2018	Medical Education Content Creator Clinical Care Solutions, Baltimore, MD
Medical University of South Carolina		
Opal Bacon, PharmD, BCPP	2015 (PGY1), 2016	Clinical Specialist, Psychiatry NWHCSVA, Omaha, NE
Megan May, PharmD, BCPP	2015 (PGY1), 2016	Clinical Specialist, Psychiatry Spartanburg Regional Health, Spartanburg, SC
Dan McGraw, PharmD, BCPP	2014 (PGY1), 2015	Clinical Specialist, Psychiatry MUSC, Charleston, SC
Taylor Nichols, PharmD, BCPP	2013 (PGY1), 2014	Clinical Specialist, Psychiatry and SUD VA Phoenix Health Care, Phoenix, AZ
Michelle Jackson Colvard, PharmD, BCPP	2013	Clinical Specialist, Psychiatry and SUD Tennessee Valley VA, Nashville, TN
Clint Ross, PharmD, BCPP	2011 (PGY1), 2012	Clinical Manager MUSC, Charleston, SC

Katherine Sticca, PharmD, BCPP	2011	Clinical Editor, Drug Information - Psychiatry Elsevier, Fargo, ND
Stephanie Phan, PharmD, BCPP	2010	Clinical Specialist, Psychiatry Tampa, FL
Tiffany Jade Kreys, PharmD, BCPP	2010	Assistant Professor, Assistant Dean of Student Affairs California Northstate University COP Elk Grove, CA
Cory (Grzesik) Merrell, PharmD	2008	Clinical Pharmacist CVS Caremark, Chicago, IL
Lynette (Lemacks) Lewis, PharmD	2007 (PGY1), 2008	Switched careers; Greenville, KY
Raymond Lorenz, PharmD	2006 (PGY1), 2007	MSL Director Quest Diagnostics, Mobile, AL
Dara (Slunaker) Johnson, PharmD, BCPP	2006	Clinical Specialist, PGY2 Am Care RPD Providence Medical Group, Portland, OR
Shauna (Sutton) Garris, BCPP, BCPS	2004 (PGY1), 2005	Senior MSL AbbVie, Durham, NC
Megan (Mikeworth) Sarashinsky, BCPP	2005	Clinical Specialist, PGY2 RPD Psychiatry Richmond, VA

Postgraduate Pharmacy Residency Mentorship:

Resident	Year	Research or Chosen Mentor	Seminar	Writing Project
University of Michigan Health				
Chloe Matecki**	2025		X	X
Rowan Roseworn**	2025	Chosen mentor		
Christine Wu*	2025		X	X
Meagan Dean**	2024	Research	X	X
Chloe Matecki*	2024		X	X
Ben Fine**	2024		X	X
Nour Kadouh*	2023		X	X
Olivia Ramirez*	2023		X	X
Amoreena Most*	2023		X	X
Ashlynn Whitsell*	2023		X	X
Meagan Dean*	2023		X	X
Marina Capitanov**	2023	Research	X	X
Christy Khoudercha*	2022	Chosen mentor		
Nick Nelson**	2022	Chosen mentor		
Abby Schwery**	2022		X	X
Michelle Nguyen*	2022		X	X
Annesti Elmsari*	2022		X	X
Morgan Marriott*	2022		X	X
Pia Roa**	2022		X	X
Hannah Christensen**	2022	Research	X	X
Megan Ingebrigstson**	2021	Chosen mentor		
Autumn Walkerly**	2021	Research	X	X
Roberta Wilson**	2021		X	X
Colin Finley**	2021		X	X
CC Wartman*	2021		X	X
Kelsey Ernst*	2021	Research		
Nick Franz**	2020	Chosen mentor		
Joe Cusimano**	2020	Research	X	X
Madison Irwin*	2020		X	X
Megan O'Connell**	2019	Research	X	X
Joe Cusimano*	2019	Research	X	X

Kyle Quirk*	2019		X	X
Alex Bixby*	2018		X	X
Jenn Erley*	2018			X
Sarah Goldsborough	2018	Research	X	X
Medical University of South Carolina				
Opal Bacon**	2016	X		
Meghan May**	2016			
Opal Bacon*	2015			
Dan McGraw	2015	X	X	X
Michelle Jackson**	2013	X		X
Clint Ross**	2012	X	X	X
Kathryn Freeland**	2011	Research	X	X
Clint Ross*	2011	Research	X	X
Stephanie Phan**	2010	Research	X	X
Tiffany Jade Kreys**	2010	Research	X	X
Lynette Lemacks*	2007	Research	X	X
Raymond Lorenz**	2007	Research	X	X
Raymond Lorenz*	2006	Research	X	X
Dara Slunaker**	2006	Research	X	X
Megan Mikeworth*	2005	Research	X	X
Shauna Garris*	2005	Research	X	X
Wendy Bullington*	2005	Research		

*: PGY1 Resident; **PGY2 Specialty Resident

Postgraduate Pharmacy Residency Rotations:

Years	Residency Program	# of Resident Rotation Months
University of Michigan Health		Total: 127
2023 to present	PGY2 Emergency Medicine Pharmacy	1
2023 to present	PGY2 Pediatric Pharmacy	1
2020 to present	PGY2 Pain and Palliative Care Pharmacy	5
2017 to present	PGY2 Psychiatric Pharmacy	80
2016 to present	PGY1 Pharmacy	40
Medical University of South Carolina		Total: 267
2003 to 2016	PGY2 Psychiatric Pharmacy	140
2003 to 2016	PGY1 Pharmacy	145

Professional Organization Activities

2022 to 2024	American Society of Addiction Medicine Benzodiazepine Tapering Clinical Guideline Committee
2021 to present	Southeastern Michigan Society of Health-System Pharmacists member
2015 to 2017	ASHP PGY2 Psychiatric Pharmacy Residency Standards Workgroup
1999 to present	College of Psychiatric and Neurologic Pharmacists (American Academy of Psychiatric Pharmacists as of 2022)
2008 to 2009	CPNP Annual Meeting Programming Committee
2006 to 2013	CPNP National Alliance on Mental Illness Relationship Management Group
2004 to 2006	Membership Committee – Mentoring Taskforce
1998 to present	American Society of Health-System Pharmacists, member

Peer Reviewer for Health Science Journals and Textbooks:

2023	Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
2023	Psychiatry Research Case Reports
2019 to present	Journal of Clinical Psychopharmacology
2019	Advanced Pediatrics Therapeutics, 2 nd Edition, ADHD Chapter
2017 to 2024	Current Psychiatry
2010 to present	Annals of Pharmacotherapy

External Advisory Board, Consultancy and Lobbying:

Year	Entity	Activity
2024 to present	NORC	Clinical consultant, content expert for scoping review of LAI Antipsychotic vs PO antipsychotics
2024	Staff of US Senators Sheldon Whitehouse and John Thune	Promote psychiatric pharmacists as qualified health providers under Medicare
August 5, 2023	The New York Times	Interviewed for "F.D.A approves the first pill to aid postpartum depression" Pam Belluck
2023	Staff of Senator Debbie Stabenow	Promote psychiatric pharmacists as qualified health providers under Medicare
2023	Plaintiff Attorney	Medical record review
2022	Defendant Attorney	Medical record review
2021	Plaintiff Attorney	Medical record review
2019 to present	Wolters-Kluwer, Lexicomp	Clinical Consultant, content expert psychotropics and neurologic medications
2015	Plaintiff Attorney	Medical record review
2010	Public Defender, State of SC	Medical record review and expert witness testimony for criminal trial
2001 to 2006	Brand Institute, Inc	Nomenclature Advisory Board Reviewer

Committees and Administrative Services***State-wide***

2023 to present Overdose Fatality Review Committee (Washtenaw County group)

University of Michigan College of Pharmacy

2024 to present Ability Based Outcome Revision Team

2022 to present Therapeutic Problem Solving (TPS) Committee

Michigan Medicine Health

2018 to 2021 Michigan Medicine 9C Steering Committee/Improving the Patient Experience Committee

2017 to 2022 Michigan Medicine Medication Reconciliation Oversight Committee

2016 to present Michigan Medicine Pharmacy & Therapeutics Committee ad hoc guest for all neurologic and psychiatric medication related discussions

2016 to present Michigan Medicine Interdisciplinary Restraint Reduction Committee

2016 to 2018 Michigan Medicine Inpatient Psychiatry Leadership Team

2016 to present Michigan Medicine Residency Advisory Committee

Medical University of South Carolina Health/Institute of Psychiatry (IOP)

2014 to 2016 MUSC IOP Epic Local Governance Team

2008 to 2016 MUSC Psychiatry Residency Curriculum Committee

2008 to 2016 MUSC IOP Clinical Executive Committee

2006 to 2010 MUSC Medication Reconciliation Taskforce

2006 to 2009 MUSC IOP Engagement Model Roll-out Committee (ad hoc)

2005 to 2016 MUSC IOP Executive Quality Council/Executive Council for Clinical Operations

2005 to 2008 MUSC IOP Practice Council

2005 to 2008 MUSC IOP Research and Outcomes Committee

2005 to 2016 MUSC Safety Committee (ad hoc)

2004 to 2012 MUSC IOP General Adult Unit Leadership Planning Committee

2003 to 2008 MUSC Falls Committee/Safety Committee

2003 to 2016 MUSC Informatics and Formulary Subcommittee

2002 to 2016 MUSC Medication Safety Improvement Group – IOP representative

2002 to 2016 MUSC IOP Hospitalist Team

2002 to 2016 MUSC Pharmacy & Therapeutics, Psychiatric Pharmacy representative

2002 to 2016 MUSC Pharmacy Residency Committee

Staff Training and Professional Development

2024	Interprofessional development of Cornerstone module on managing EPS (Children's Hospital nursing staff)
2024	Nursing education: Ketamine for agitation (PES nursing staff)
2024	Managing insulin on inpatient psychiatry services: (MD, NP, PA, RN)
2022	Residency preceptor training (1 hour): Providing constructive feedback
2021	Psychiatric Pharmacy and Thoughts on Wellness: Purdue APhA-ASP guest speaker
2021	Update on rating scales for Psychiatry PRNs (RN and prescribers)
2020	Wellness, Resilience and Burnout in pharmacy training: UM APhA-ASP guest speaker
2019	Accuracy of LAI medications on after visit summary: all inpatient psychiatry prescribers
2018 to present	Annual pharmacy resident orientation session on professionalism and wellness
2017 to 2020	Pharmacy residency teaching certificate program facilitator: precepting challenges
2017	Use of Psychiatry PRN order sets for patient safety and Joint Commission compliance
2010 to 2016	Annual pharmacy resident orientation session on professionalism
2006 to 2016	Pharmacy residency teaching certificate program: precepting challenges
2014 to 2014	Children's Day Treatment Program: annual staff education on psychopharmacology
2002 to 2016	New Employee Orientation: Psychopharmacology Review: new hire interdisciplinary staff at the Institute of Psychiatry

Volunteer Activities

2018	Student Run Free Clinic – Pinckney, MI
2014	Habitat for Humanity - Charleston
2004 to 2012	Harvest Free Medical Clinic –Volunteer Pharmacy Services Coordinator